CompletedNCT02368340
A Longitudinal Study of Hermansky-Pudlak Syndrome Pulmonary Fibrosis
Studying Syndromic oculocutaneous albinism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vanderbilt University
- Principal Investigator
- Lisa R. Young, MDVanderbilt University
- Intervention
- Pulmonary function test(other)
- Enrollment
- 55 enrolled
- Eligibility
- 12-90 years · All sexes
- Timeline
- 2015 – 2019
Study locations (5)
- Loyola University Medical Center, Maywood, Illinois, United States
- Brigham and Women's Hospital, Harvard, Boston, Massachusetts, United States
- Columbia University Medical Center, New York, New York, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Vanderbilt University, Nashville, Tennessee, United States
Collaborators
University of South Florida · National Institutes of Health (NIH) · National Heart, Lung, and Blood Institute (NHLBI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02368340 on ClinicalTrials.govOther trials for Syndromic oculocutaneous albinism
Additional recruiting or active studies for the same condition.